First Time Loading...

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 135.9 USD -0.75% Market Closed
Updated: Apr 28, 2024

Ascendis Pharma A/S
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascendis Pharma A/S
Revenue Peer Comparison

Comparables:
GMAB
ZEAL
B
BAVA
BIOPOR
SANION

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Revenue
€266.7m
CAGR 3-Years
237%
CAGR 5-Years
91%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Revenue
kr16.5B
CAGR 3-Years
18%
CAGR 5-Years
40%
CAGR 10-Years
38%
Zealand Pharma A/S
CSE:ZEAL
Revenue
kr342.8m
CAGR 3-Years
21%
CAGR 5-Years
55%
CAGR 10-Years
48%
B
Bavarian Nordic A/S
CSE:BAVA
Revenue
kr7.1B
CAGR 3-Years
56%
CAGR 5-Years
70%
CAGR 10-Years
19%
Bioporto A/S
CSE:BIOPOR
Revenue
kr31m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
6%
Saniona AB
STO:SANION
Revenue
kr16.8m
CAGR 3-Years
27%
CAGR 5-Years
-21%
CAGR 10-Years
N/A

See Also

What is Ascendis Pharma A/S's Revenue?
Revenue
266.7m EUR

Based on the financial report for Dec 31, 2023, Ascendis Pharma A/S's Revenue amounts to 266.7m EUR.

What is Ascendis Pharma A/S's Revenue growth rate?
Revenue CAGR 5Y
91%

Over the last year, the Revenue growth was 421%. The average annual Revenue growth rates for Ascendis Pharma A/S have been 237% over the past three years , 91% over the past five years .